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Background: Does improved exercise capacity after treatment with enhanced external counterpulsation (EECP) decrease the risk for 
major adverse cardiac events (MACE) by mobilizing endothelial precursor cells (EPC) to enhance coronary collateral circulation?
methods: Forty consecutive patients with angina refractory to revascularization and medical treatment received stress testing before 
and after EECP,a weekly blood test for EPC CD34+/KDR+ or CD34+/CD133+ cells and were followed for MACE. A control group of 9 
consecutive cardiac rehabilitation (CR) patients received similar testing. Ten CD34+/CD133+ samples were tested for clonigenic potential 
in vitro.
results: Both double product (DP) and treadmill times (TT) were improved in 36% of EECP and 44% of CR patients. Those improved 
EECP patients had significantly (p=0.032) higher levels of CD34+/CD133+ cells during treatment than non-responders (Table) and 
a significantly (p=0.026) reduced hazard rate (HR = 0.22, 95% C.I. = 0.08-0.62) of MACE afterwards. CR responders did not have 
significantly (p=0.128) different CD34+/CD133+ cell levels during treatment. CD34+/CD133+ cells during EECP had greater colonigenic 
potential (18±1 colonies) than at the start of therapy (7±2 colonies) or healthy controls (2±1 colonies, p<0.0001).
Conclusion:  Improved exercise capacity after EECP correlated with increases in EPC and reduced MACE. CR patients with improved 
exercise capacity do not experience a corresponding increase in CD34+/CD133+ EPC counts.
CD34+/CD133+ cell counts increase over the course of EECP in clinically improved patients
Treatment 
Week Clinically improved(Both DP and TT Improved) Clinically not improved (DP or TT Not Imptoved)
1 36±13* 39±11
2 31±14 34±11
3 25±15 38±12
4 51±15 32±12
5 83±14** 10±13
6 81±17** 21±14
7 107±16** 75±32
**significantly greater than corresponding not improved group P<0.05 *CD34+/CD133+ cell counts/100,000 monocytes
